Ikeda, M.; Fujimoto, K.; Miura, N.; Taoka, R.; Nishihara, K.; Ikarashi, D.; Naito, S.; Shimizu, F.; Fujihara, A.; Shono, M.;
et al. A Multicenter Retrospective Study of Avelumab First-Line Maintenance and Subsequent Therapies for Locally Advanced and Metastatic Urothelial Carcinoma: Subgroup Analysis of First-Line Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, and Gemcitabine Plus Cisplatin in the Japan AVElumab MAintenance and Continuous Treatment Study (JAVEMACS). Curr. Oncol. 2025, 32, 618.
https://doi.org/10.3390/curroncol32110618
AMA Style
Ikeda M, Fujimoto K, Miura N, Taoka R, Nishihara K, Ikarashi D, Naito S, Shimizu F, Fujihara A, Shono M,
et al. A Multicenter Retrospective Study of Avelumab First-Line Maintenance and Subsequent Therapies for Locally Advanced and Metastatic Urothelial Carcinoma: Subgroup Analysis of First-Line Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, and Gemcitabine Plus Cisplatin in the Japan AVElumab MAintenance and Continuous Treatment Study (JAVEMACS). Current Oncology. 2025; 32(11):618.
https://doi.org/10.3390/curroncol32110618
Chicago/Turabian Style
Ikeda, Masaomi, Kiyohide Fujimoto, Noriyoshi Miura, Rikiya Taoka, Kiyoaki Nishihara, Daiki Ikarashi, Sei Naito, Fumitaka Shimizu, Atsuko Fujihara, Michihiro Shono,
and et al. 2025. "A Multicenter Retrospective Study of Avelumab First-Line Maintenance and Subsequent Therapies for Locally Advanced and Metastatic Urothelial Carcinoma: Subgroup Analysis of First-Line Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, and Gemcitabine Plus Cisplatin in the Japan AVElumab MAintenance and Continuous Treatment Study (JAVEMACS)" Current Oncology 32, no. 11: 618.
https://doi.org/10.3390/curroncol32110618
APA Style
Ikeda, M., Fujimoto, K., Miura, N., Taoka, R., Nishihara, K., Ikarashi, D., Naito, S., Shimizu, F., Fujihara, A., Shono, M., Nakagawa, T., & Kikuchi, E.
(2025). A Multicenter Retrospective Study of Avelumab First-Line Maintenance and Subsequent Therapies for Locally Advanced and Metastatic Urothelial Carcinoma: Subgroup Analysis of First-Line Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, and Gemcitabine Plus Cisplatin in the Japan AVElumab MAintenance and Continuous Treatment Study (JAVEMACS). Current Oncology, 32(11), 618.
https://doi.org/10.3390/curroncol32110618
